Food and Drug Administration

Advisory Committee for Pharmaceutical Science

Clinical Pharmacology Subcommittee

November 18, 2003

CYP2B6/CYP2C8 and Drug Interactions: Introduction, Dr. Shiew-Mei Huang, PhD, FDA (HTM) (PPT)

CYP2B6 and Drug Interactions, Dr Zeruesenay Desta, PhD and Dr. David Flockhart, MD, PhD, Indiana University School of Medicine (HTM) (PPT)

CYP2C8 and Drug Interactions, Dr. Pertti Neuvonen, MD, Helsinki, Finland (HTM) (PPT)

Pharmacogenetics: Integration Into New Drug Development, Dr. Lawrence Lesko, PhD, FCP, FDA (HTM) (PPT)

Pharmacogenetics: Integration Into New Drug Development - Academic Perspective, Dr. David Flockhart, MD PhD, Indiana University School of Medicine (HTM) (PPT)

Strattera Case Study - Answers That Matter, Dr. Richard Hockett, Jr., MD, Lilly (HTM) (PPT)

Clinical Perspective on Pharmacogenetic Labeling, Dr. Reling (HTM) (PPT)